AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Genworth today, you have to believe its transition story holds together: that capital coming up from Enact can keep supporting buybacks and CareScout investment, while the legacy long term care block remains contained. The recent move to stop new LTC sales in Genworth Life and roll out CareScout’s product in 40 states reinforces that pivot and could sharpen near term catalysts around uptake of the new platform and ongoing capital returns from Enact. At the same time, the Closed Block still anchors the risk side of the thesis, alongside modest recent earnings, low return on equity and forecasts pointing to weaker profits. So far, the share price has not reacted in a way that suggests the CareScout news has fundamentally reset expectations, but it does slightly tilt the balance between growth optionality and run off risk.
But that growth optionality sits next to a very real long term care risk that investors should understand. Genworth Financial's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.One Simply Wall St Community member pegs fair value very close to the current price, highlighting how individually modeled views can cluster. Set that against the shifting mix of Enact driven capital returns and long term care exposure, and you get a reminder that different investors can look at the same numbers and reach very different conclusions about Genworth’s resilience and upside potential.
Explore another fair value estimate on Genworth Financial - why the stock might be worth less than half the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com